These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
258 related items for PubMed ID: 25846209
1. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Nony E, Bouley J, Le Mignon M, Lemoine P, Jain K, Horiot S, Mascarell L, Pallardy M, Vincentelli R, Leone P, Roussel A, Batard T, Abiteboul K, Robin B, de Beaumont O, Arvidsson M, Rak S, Moingeon P. Allergy; 2015 Jul; 70(7):795-804. PubMed ID: 25846209 [Abstract] [Full Text] [Related]
4. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. Tourdot S, Airouche S, Berjont N, Moussu H, Betbeder D, Nony E, Bordas-Le Floch V, Baron-Bodo V, Mascarell L, Moingeon P. Vaccine; 2013 May 28; 31(23):2628-37. PubMed ID: 23583462 [Abstract] [Full Text] [Related]
6. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. Pfaar O, Bachert C, Kuna P, Panzner P, Džupinová M, Klimek L, van Nimwegen MJ, Boot JD, Yu D, Opstelten DJE, de Kam PJ. J Allergy Clin Immunol; 2019 Mar 28; 143(3):970-977. PubMed ID: 30508538 [Abstract] [Full Text] [Related]
7. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis. Mäkelä MJ, Gyllfors P, Valovirta E, Steffensen MA, Grønager PM, Savolainen J, Winther L. Clin Ther; 2018 Apr 28; 40(4):574-586.e4. PubMed ID: 29551533 [Abstract] [Full Text] [Related]
8. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit. Ellis AK, Tenn MW, Steacy LM, Adams DE, Day AG, Walker TJ, Nolte H. Ann Allergy Asthma Immunol; 2018 May 28; 120(5):495-503.e2. PubMed ID: 29432967 [Abstract] [Full Text] [Related]
10. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model. Siebeneicher S, Reuter S, Wangorsch A, Krause M, Foetisch K, Heinz A, Naito S, Reuter A, Taube C, Vieths S, Scheurer S, Toda M. Allergy; 2015 Dec 28; 70(12):1559-68. PubMed ID: 26304061 [Abstract] [Full Text] [Related]
16. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Gafvelin G, Thunberg S, Kronqvist M, Grönlund H, Grönneberg R, Troye-Blomberg M, Akdis M, Fiebig H, Purohit A, Horak F, Reisinger J, Niederberger V, Akdis CA, Cromwell O, Pauli G, Valenta R, van Hage M. Int Arch Allergy Immunol; 2005 Sep 28; 138(1):59-66. PubMed ID: 16103688 [Abstract] [Full Text] [Related]
18. Quality and potency profile of eight recombinant isoallergens, largely mimicking total Bet v 1-specific IgE binding of birch pollen. Seutter von Loetzen C, Reuter A, Spiric J, Schulenborg T, Bellinghausen I, Völker E, Vogel L, Rösch P, Schiller D. Clin Exp Allergy; 2019 May 28; 49(5):712-723. PubMed ID: 30706562 [Abstract] [Full Text] [Related]
19. Recombinant marker allergens in diagnosis of patients with allergic rhinoconjunctivitis to tree and grass pollens. Canis M, Gröger M, Becker S, Klemens C, Kramer MF. Am J Rhinol Allergy; 2011 May 28; 25(1):36-9. PubMed ID: 21711974 [Abstract] [Full Text] [Related]
20. Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4. Shirasaki H, Yamamoto T, Koyanagi Y, Watanabe N, Himi T. Allergol Int; 2008 Mar 28; 57(1):93-6. PubMed ID: 18209509 [Abstract] [Full Text] [Related] Page: [Next] [New Search]